Skip to main content
SpringerLink
Log in
Book cover

Handbuch Gastroenterologie 2010 pp 37–74Cite as

Onkologie: Ösophagus/Magen/Dünndarm

  • Conference paper

  • 1093 Accesses

Part of the book series: Handbuch Update-Seminar ((UPDATESEMINAR))

Zusamenfassung

In dieser Metaanalyse von 20 randomisierten Studien mit über 200.000 Teilnehmern wurde die Wirkung von Betakarotin, der Vitamine A, C und E und von Selen untersucht. Es fand sich keine Evidenz für eine Prävention gastrointestinaler Karzinome (RR 0,94; 95% CI: 0,83-1,06). Im Gegenteil, sie erhöhten sogar die Gesamtmortalität (1,04; 1,02–1,07).

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

2.8 Literatur

  1. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Systematic review: primary and secondary prevention of gastrointestinal cancers with antioxidant supplements. Aliment Pharmacol Ther 2008;28:689–703.

    Article  CAS  PubMed  Google Scholar 

  2. Sant M, Allemani C, Santaquilani M, et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. EJC 2009;45(6):931–991.

    Article  Google Scholar 

  3. Francisci S, Capocaccia R, Grande E, et al. The cure of cancer: A European perspective. EJC 2009;45:1067–1079.

    Article  Google Scholar 

  4. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response criteria in solid tumours: Revised RECIST guideline (version 1.1). EJC 2009;45:228–247.

    Article  CAS  Google Scholar 

  5. Rapoport BL, Jordan K, Boice JA, et al. Aprepitant fort he prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer Springer 2009;Band 0, Nr. 0:1–9. (DOI 10.1007/s00520-009-0680-9).

    Google Scholar 

  6. Pandeya N, Williams G, Green AC, et al. Alcohol Consumption and the Risks of Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus. Gastroenterology 2009;136:1215–1224.

    Article  CAS  PubMed  Google Scholar 

  7. Anderson LA, Cantwell MM, Watson RGP, et al. The Association Between Alcohol and Reflux Esophagitis, Barrett’s Esophagus, and Esophageal Adenocarcinoma. Gastroenterology 2009;136:799–805.

    Article  PubMed  Google Scholar 

  8. Islami F, Boffetta P, Ren JS, et al. High-temperature beverages and foods and esophageal cancer — A systematic review. Int J Cancer 2009;125:491–524.

    Article  CAS  PubMed  Google Scholar 

  9. Kubo A, Levin TR, Block G, et al. Dietary antioxidants, fruits, and vegetables and the risk of Barrett’s esophagus. Am J Gastroenterol 2008;103:1614–1623.

    Article  CAS  PubMed  Google Scholar 

  10. Corley DA, Kubo A, Levin TR, et al. Racem ethnicity, sex and temporal differences in Barrett’s oesophagus diagnosis: a large community-based study, 1994-2006. Gut 2009;58:182–188.

    Article  CAS  PubMed  Google Scholar 

  11. Wani S, Puli SR, Shaheen NJ, et al. Esophageal adenocarcinoma in Barrett’s esophagus after endoscopic ablative therapy: A meta-analysis and systematic review. Am J Gastroenterol 2009;104:502–513.

    Article  PubMed  Google Scholar 

  12. Djärv T, Blazeby JM, Lagergren P. Predictors of Postoperative Quality of Life After Esophagectomy for Cancer. J Clin Oncol 2009;27:1963–1968.

    Article  PubMed  Google Scholar 

  13. Bollschweiler E, Metzger R, Drebber U, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 2009;20:231–238.

    Article  CAS  PubMed  Google Scholar 

  14. Allum WH, Stenning SP, Bancewicz J, et al. Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer. J Clin Oncol 2009;27:5062–5067.

    Article  PubMed  Google Scholar 

  15. Sarkaria IS, Rizk Np, Bains MS, et al. Post-treatment endoscopic biopsy is a poor predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg 2009;249:764–767.

    Article  PubMed  Google Scholar 

  16. Rizk NP, Tang L, Adusumilli PS, et al. Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol 2009;4:875–879.

    Article  PubMed  Google Scholar 

  17. Javeri H, Xiao L, Rohren E, et al. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer 2009;115:624–630.

    Article  PubMed  Google Scholar 

  18. Javeri H, Xiao L, Rohren E, et al. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer 2009;115:5184–5192.

    Article  PubMed  Google Scholar 

  19. Starling N, Rao S, Cunningham D, et al. Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoro-pyrimidine Combination Chemotherapy: A Report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009;27:3786–3793.

    Article  CAS  PubMed  Google Scholar 

  20. Khorana AA, Connolly GC. Assessing Risk of Venous Thromboembolism in the Patient With Cancer. J Clin Oncol 2009;27:4839–4847.

    Article  CAS  PubMed  Google Scholar 

  21. Francis CW. Prevention of Venous Thromboembolism in Hospitalized Patients With Cancer. J Clin Oncol 2009;27:4874–4880.

    Article  CAS  PubMed  Google Scholar 

  22. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009;20:1667–1773.

    Article  CAS  PubMed  Google Scholar 

  23. Yang P, Zhou Y, Chen B, et al. Overweight, obesity and gastric cancer risk: Results from a meta-analysis of cohort studies. Eur J Cancer 2009;doi:10.1016/j.ejca.2009.04.019

    Google Scholar 

  24. Ikeda F, Doi Y, Yonemoto K, et al. Hyperglycemia Increases Risk of Gastric Cancer Posed by Helicobacter pylori Infection: A Population-Based Cohort Study. Gastroenterology 2009;136:1234–1241.

    Article  CAS  PubMed  Google Scholar 

  25. Myung SK, Bae WK, Oh SM, et al. Green tea consumption and risk of stomach cancer: A meta-analysis of epidemiologic studies. Int J Cancer 2009;124:670–677.

    Article  CAS  PubMed  Google Scholar 

  26. Inoue M, Sasazuki S, Wakai K, et al. Green tea consumption and gastric cancer in Japanese: a pooled analysis of six cohort studies. Gut 2009;58:1323–1332.

    Article  CAS  PubMed  Google Scholar 

  27. Liu H, Merrell DS, Semino-Mora C, et al. Diet Synergistically Affects Helicobacter pylori-induced Gastric Carcinogenesis in Nonhuman Primates. Gastroenterology 2009;137:1367–1379.

    Article  CAS  PubMed  Google Scholar 

  28. Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis Shows That Prevalence of Epstein-Barr Virus-Positive Gastric Cancer Differs Based on Sex and Anatomic Location. Gastroenterology 2009;137:824–833.

    Article  PubMed  Google Scholar 

  29. Poulsen AH, Christensen S, McLaughlin JK, et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.

    Google Scholar 

  30. Ren JS, Kamangar F, Qiao YL, et al. Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort. Gut 2009;58:636–642.

    Article  CAS  PubMed  Google Scholar 

  31. Wu CY, Kuo KN, Wu MS, et al. Early Helicobacter pylori Eradication Decreases Risk of Gastric Cancer in Patients With Peptic Ulcer Disease. Gastroenterology 2009;137:1641–1648.

    Article  PubMed  Google Scholar 

  32. Kokkola A, Sipponen P, Arkkila P, et al. Does the eradication of Helicobacter pylori delay the diagnosis of gastric cancer? Scand J Gastroenterol 2008;43:1456–1460.

    Article  PubMed  Google Scholar 

  33. Fuccio L, Zagari RM, Eusebi MH, et al. Meta-analysis: Can Helicobacter pylori Eradication Treatment Reduce the Risk for Gastric Cancer? Ann Intern Med 2009;151:121–128.

    PubMed  Google Scholar 

  34. Watanabe Y, Kim HS, Castoro RJ, et al. Sensitive and Specific Detection of Early Gastric Cancer with DNA Methylation Analysis of Gastric Washes. Gastroenterology 2009;136: 2149–2158.

    Article  CAS  PubMed  Google Scholar 

  35. Schwartz GK, Winter K, Minsky BD, et al. Randomized Phase II Trial Evaluating Two Paclitaxel and Cisplatin-Containing Chemoradiation Regimens As Adjuvant Therapie in Resected Gastric Cancer (RTOG-0114). J Clin Oncol 2009;27:1956–1962.

    Article  CAS  PubMed  Google Scholar 

  36. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction. J Clin Oncol 2009;27:851–856.

    Article  CAS  PubMed  Google Scholar 

  37. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;doi:10.1093/annonc/mdn717.

    Google Scholar 

  38. Capelle LG, de Vries AC, Looman CWN, et al. Gastric MALT lymphoma: Epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer 2008;44:2470–2476.

    Article  CAS  PubMed  Google Scholar 

  39. Siakantaris M, Pangalis GA, Dimitriadou E, et al. Early-Stage Gastric MALT Lymphoma: Is It a Truly Localized Disease? The Oncologist 2009;14:148–154.

    Article  PubMed  Google Scholar 

  40. Enomoto K, Hamada K, Inohara H, et al. Mucosa-associated lymphoid tissue lymphoma studied with FDG-PET: a comparison with CT and endoscopic findings. Ann Nucl Med 2009;22.261–267.

    Article  Google Scholar 

  41. Perry C, Herishanu Y, Metzer U, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Hematol 2007;79:205–209.

    Article  Google Scholar 

  42. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin’s Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review. J Clin Oncol 2009;27:1906–1914.

    Article  PubMed  Google Scholar 

  43. Vaira D et al. Long-term remission rate of early-stage gastric MALT-lymphoma and predictive factors following H. pylori eradication. Clin Gastroenterol Hepatol, epub ahead

    Google Scholar 

  44. Zullo A, Hassan C, Andriani A, et al. Eradication Therapy for Helicobacter pylori in Patients With gastric MALT Lymphoma: A Pooled Data Analysis. Am J Gastroenterol 2009;104:1932–1937.

    Article  CAS  PubMed  Google Scholar 

  45. Le Cesne A, Van Glabbeke M, Verweij J, et al. Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumours Predicts Survival in Advanced Gl Stromal Tumours Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial. J Clin Oncol 2009;27:3969–3974.

    Article  Google Scholar 

  46. Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumours. J Clin Oncol 2009;27:439–445.

    Google Scholar 

  47. DeMatteo RP, Ballman K, Antonescu C, et al. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumour: a randomized, double-blind, placebo-controlled trial. Lancet 2009;373:1097–1104.

    Article  CAS  PubMed  Google Scholar 

  48. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959–1968.

    Article  CAS  PubMed  Google Scholar 

  49. Montemurro M, Schöffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009;45:2293–2297.

    Article  CAS  PubMed  Google Scholar 

  50. Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumours: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl4): iv64–iv67.

    Article  Google Scholar 

  51. Pantaleo MA, Nannini M, Di Battista M, et al. Combined treatment strategies in gastrointestinal stroma tumors (GISTs) after imatinib and sunitinib therapy. Cancer Treat Rev 2009;doi:10.1016/j.ctrv.2009.10.004

    Google Scholar 

  52. Blay M. Pharmacological management of gastrointestinal stroma tumours: an update on the role of sunitinib. Ann Oncol 2009;doi:10.1093(annonc/mdp291.

    Google Scholar 

  53. Reichardt P. Second-line treatment options in GIST. Advances in Oncology 2008;3:8–13.

    Google Scholar 

  54. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group. J Clin Oncol 2009;27:4656–4663.

    Article  CAS  PubMed  Google Scholar 

  55. Overman MJ, Varadhachary GR, Kopetz S, et al. Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 2009;27:2598–2603.

    Article  CAS  PubMed  Google Scholar 

  56. Gao Y, Kristinsson SY, Goldin LR, et al. Increased Risk for Non-Hodgkin Lymphoma in Individuals With Celiac Diasease and a Potential Familial Association. Gastroenterology 2009;136:91–98.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. II. Medizinische Klinik, Klinikum Aschaffenburg, Am Hasenkopf 1, 63739, Aschaffenburg, Deutschland

    Prof. Dr. Wolfgang Fischbach

Authors
  1. Prof. Dr. Wolfgang Fischbach
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kiinik für Aiigemein- und Viszeraichirurgie, Dr. Horst Schmidt Kiiniken GmbH, Ludwig-Erhard-Straße 100, 65199, Wiesbaden

    Christian Eli

  2. Medizinische Klinik, Israelitisches Krankenhaus, Orchideenstieg 14, 22297, Hamburg

    Peter Layer

  3. II. Medizinische Kiinik, Kiinikum Aschaffenburg, Am Hasenkopf 1, 63739, Aschaffenburg

    Wolfgang Fischbach

  4. Chirurgisches Zentrum Viszeral-, Gefäß- und Endokrine Chirurgie, HELlOS Kiinikum Wuppertal, Heusnerstraße 40, 42283, Wuppertai

    Hubert Zirngibl

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Medizin Verlag Heidelberg

About this paper

Cite this paper

Fischbach, W. (2010). Onkologie: Ösophagus/Magen/Dünndarm. In: Eli, C., Layer, P., Fischbach, W., Zirngibl, H. (eds) Handbuch Gastroenterologie 2010. Handbuch Update-Seminar. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-11635-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-11635-3_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-11634-6

  • Online ISBN: 978-3-642-11635-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation